Abbmira Therapeutics AG

Cancer immunotherapies are effective in only 30% of patients. Failure in treatment is due to "cold" tumor microenvironments dominated by pro-tumorigenic tumor-associated macrophages (TAMs) that hinder the appropriate immune response. Abbmira Therapeutics aims to turn these cold tumors hot, targeting TAMs to activate anticancer immunity. The small molecule Compound42 was designed to target TAMs & proof-of-concept experiments confirm it stops cancer growth in mice. Abbmira will address an unmet biomedical need & aims to revolutionise the immuno-oncology market, estimated at $37B in 2022, growing to $169B by 2032. Abbmira's founding teamoffers 50+ years of combined experience in business, pharma, and life sciences.